News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
721,649 Results
Type
Article (40900)
Company Profile (267)
Press Release (680472)
Multimedia
Podcasts (81)
Webinars (17)
Section
Business (204665)
Career Advice (2023)
Deals (35532)
Drug Delivery (110)
Drug Development (81380)
Employer Resources (173)
FDA (16408)
Job Trends (14944)
News (346377)
Policy (32725)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (2)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2567)
Accelerated approval (31)
Adcomms (24)
Allergies (142)
Alliances (49575)
ALS (169)
Alzheimer's disease (1667)
Antibody-drug conjugate (ADC) (308)
Approvals (16677)
Artificial intelligence (514)
Autoimmune disease (153)
Automation (39)
Bankruptcy (361)
Best Places to Work (11636)
BIOSECURE Act (20)
Biosimilars (188)
Biotechnology (174)
Bladder cancer (157)
Brain cancer (56)
Breast cancer (637)
Cancer (4794)
Cardiovascular disease (398)
Career advice (1708)
Career pathing (36)
CAR-T (280)
CDC (44)
Celiac Disease (2)
Cell therapy (739)
Cervical cancer (36)
Clinical research (69553)
Collaboration (1697)
Company closure (4)
Compensation (1156)
Complete response letters (54)
COVID-19 (2710)
CRISPR (88)
C-suite (841)
Cystic fibrosis (143)
Data (6212)
Decentralized trials (2)
Denatured (25)
Depression (131)
Diabetes (500)
Diagnostics (6686)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (251)
Drug pricing (184)
Drug shortages (28)
Duchenne muscular dystrophy (231)
Earnings (90157)
Editorial (56)
Employer branding (21)
Employer resources (152)
Events (117266)
Executive appointments (971)
FDA (19516)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (11)
Frontotemporal dementia (23)
Funding (1465)
Gene editing (194)
Generative AI (43)
Gene therapy (593)
GLP-1 (965)
Government (4659)
Grass and pollen (6)
Guidances (383)
Healthcare (18872)
HIV (58)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (249)
Immuno-oncology (57)
Indications (110)
Infectious disease (2978)
Inflammatory bowel disease (187)
Inflation Reduction Act (14)
Influenza (116)
Intellectual property (248)
Interviews (315)
IPO (16642)
IRA (50)
Job creations (3642)
Job search strategy (1428)
JPM (57)
Kidney cancer (16)
Labor market (85)
Layoffs (546)
Leadership (31)
Legal (7949)
Liver cancer (91)
Longevity (14)
Lung cancer (646)
Lymphoma (375)
Machine learning (42)
Management (59)
Manufacturing (790)
MASH (163)
Medical device (13768)
Medtech (13821)
Mergers & acquisitions (19960)
Metabolic disorders (1265)
Multiple sclerosis (160)
NASH (16)
Neurodegenerative disease (314)
Neuropsychiatric disorders (88)
Neuroscience (2890)
Neurotech (1)
NextGen: Class of 2026 (6519)
Non-profit (4514)
Now hiring (67)
Obesity (593)
Opinion (257)
Ovarian cancer (166)
Pain (197)
Pancreatic cancer (226)
Parkinson's disease (279)
Partnered (33)
Patents (494)
Patient recruitment (487)
Peanut (56)
People (58863)
Pharmaceutical (62)
Pharmacy benefit managers (29)
Phase 1 (21683)
Phase 2 (30612)
Phase 3 (22803)
Pipeline (5259)
Policy (281)
Postmarket research (2564)
Preclinical (9196)
Press Release (64)
Prostate cancer (237)
Psychedelics (48)
Radiopharmaceuticals (279)
Rare diseases (831)
Real estate (5955)
Recruiting (70)
Regulatory (24471)
Reports (52)
Research institute (2387)
Resumes & cover letters (352)
Rett syndrome (27)
RNA editing (16)
RSV (77)
Schizophrenia (147)
Series A (238)
Series B (190)
Service/supplier (11)
Sickle cell disease (95)
Special edition (21)
Spinal muscular atrophy (157)
Sponsored (41)
Startups (3614)
State (2)
Stomach cancer (17)
Supply chain (104)
Tariffs (84)
The Weekly (54)
Vaccines (1001)
Venture capital (88)
Weight loss (379)
Women's health (91)
Worklife (18)
Date
Today (211)
Last 7 days (622)
Last 30 days (2137)
Last 365 days (29969)
2026 (3376)
2025 (30172)
2024 (35215)
2023 (40075)
2022 (51174)
2021 (55710)
2020 (54084)
2019 (46538)
2018 (35018)
2017 (32109)
2016 (31480)
2015 (37553)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (736)
Alabama (83)
Alaska (7)
Arizona (309)
Arkansas (13)
Asia (39214)
Australia (6409)
California (11275)
Canada (3280)
China (1095)
Colorado (477)
Connecticut (475)
Delaware (335)
Europe (84501)
Florida (1686)
Georgia (355)
Hawaii (3)
Idaho (61)
Illinois (859)
India (65)
Indiana (519)
Iowa (22)
Japan (428)
Kansas (126)
Kentucky (38)
Louisiana (26)
Maine (72)
Maryland (1380)
Massachusetts (8075)
Michigan (324)
Minnesota (628)
Mississippi (5)
Missouri (128)
Montana (32)
Nebraska (28)
Nevada (122)
New Hampshire (78)
New Jersey (2996)
New Mexico (28)
New York (2969)
North Carolina (1447)
North Dakota (8)
Northern California (5508)
Ohio (332)
Oklahoma (21)
Oregon (41)
Pennsylvania (2275)
Puerto Rico (24)
Rhode Island (47)
South America (1108)
South Carolina (66)
South Dakota (1)
Southern California (4388)
Tennessee (174)
Texas (1737)
United States (39949)
Utah (334)
Vermont (1)
Virginia (260)
Washington D.C. (81)
Washington State (918)
West Virginia (4)
Wisconsin (107)
Wyoming (2)
721,649 Results for "celmatix inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Celmatix Launches Novel Endometriosis Drug Program
January 8, 2025
·
6 min read
Pharm Country
Celmatix Announces Breakthrough in Novel Oral Fertility Drug Program
Celmatix Inc.today announced the identification of promising early leads in its latest drug program, aimed at developing the world’s first oral FSH receptor (FSHR) agonist drug.
June 27, 2023
·
4 min read
Pharm Country
Celmatix Launches Novel PCOS Drug Program
Celmatix Inc., the leading women’s health biotech focused on ovarian biology, today announced its latest drug program, which is targeting melatonin receptors outside of the central nervous system (CNS).
April 13, 2023
·
4 min read
Business
Celmatix and Aché Laboratórios Announce Collaboration to Investigate a Novel Melatonin Receptor Agonists for Women’s Health
Celmatix Inc. and Aché Laboratórios, a leading Brazilian pharmaceutical company, announced a collaboration and license option agreement to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Aché, for Women’s Health indications.
August 8, 2023
·
4 min read
Business
Celmatix Appoints Drug Development Expert Dr. Susan Herbert to Strategic Advisory Board
Celmatix Inc the leading women’s health biotech focused uniquely on ovarian biology, today announced that Dr. Susan Herbert has joined the company’s board of advisors.
May 16, 2023
·
3 min read
Business
Celmatix and Global Collaborators Announce Findings from Largest Genetic Study to Date on Endometriosis
Celmatix Inc., the leading women’s health biotech focused on ovarian biology, today announced findings from its long-term collaboration with researchers from the University of Oxford and 24 other institutions to decode the genetic basis of endometriosis, a condition that globally impacts 1 in 10 women*
March 13, 2023
·
6 min read
Pharm Country
Celmatix Achieves Milestone for PCOS Drug Program
Celmatix Inc., a biotechnology company focused on ovarian biology, announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec.
January 18, 2022
·
3 min read
Press Releases
BioSyent to Acquire Oral Science Inc.
February 9, 2026
·
10 min read
Drug Development
Celmatix Announces Achievement of Key Preclinical Milestones in Premature Menopause Prevention Drug Program
Celmatix Inc. a biotechnology company focused on ovarian biology, announced the identification of a novel AMHR2 agonist compound that has demonstrated robust biological activity in multiple therapeutically relevant preclinical assays and a pharmacokinetic profile consistent with the desired product profile for an injectable drug.
May 16, 2022
·
3 min read
Press Releases
Convatec awarded Enterostomal Therapy Products agreements with Premier, Inc.
February 10, 2026
·
2 min read
1 of 72,165
Next